Sanofi Management

Management criteria checks 3/4

Sanofi's CEO is Paul Hudson, appointed in Sep 2019, has a tenure of 4.58 years. total yearly compensation is €10.72M, comprised of 13.1% salary and 86.9% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth €6.46M. The average tenure of the management team and the board of directors is 4.1 years and 4.8 years respectively.

Key information

Paul Hudson

Chief executive officer

€10.7m

Total compensation

CEO salary percentage	13.1%
CEO tenure	4.6yrs
CEO ownership	0.006%
Management average tenure	4.1yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Hudson's remuneration changed compared to Sanofi's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	n/a	n/a	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensation vs Market: Paul's total compensation ($USD11.47M) is above average for companies of similar size in the French market ($USD4.74M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Hudson (56 yo)

4.6yrs

Tenure

€10,718,747

Compensation

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Hudson	CEO & Director	4.6yrs	€10.72m	0.0057% € 6.5m
François-Xavier Roger	Executive VP & CFO	no data	no data	no data
Madeleine Roach	Executive VP & Head of Business Operations	less than a year	no data	no data
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	no data	no data
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	no data	no data
Eva Schaefer-Jansen	Head of Investor Relations	no data	no data	no data
Dante Beccaria	Global Compliance Officer & VP	12yrs	no data	no data
Roy Papatheodorou	Executive VP & General Counsel	2.2yrs	no data	no data
Josep Catlla	Head of Communications	no data	no data	no data
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	19.7yrs	no data	no data
Natalie Bickford	Executive VP & Chief People Officer	3.7yrs	no data	no data
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	21.9yrs	no data	no data

4.1yrs

Average Tenure

56yo

Average Age

Experienced Management: SAN's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Hudson	CEO & Director	4.5yrs	€10.72m	0.0057% € 6.5m
Jean-François Dehecq	Honorary Chairman	13.9yrs	€4.71m	no data
Serge Weinberg	Honorary Chairman	less than a year	€324.96k	0.00013% € 148.1k
Patrick Kron	Independent Director	9.9yrs	€175.75k	0.000080% € 91.1k
Lise Kingo	Independent Director	4yrs	€148.25k	0.000080% € 91.1k
Frederic Oudea	Independent Chairman	less than a year	€573.52k	0.000080% € 91.1k
Fabienne Lecorvaisier	Independent Director	10.9yrs	€156.50k	0.000080% € 91.1k
Gilles Schnepp	Independent Director	2.3yrs	€175.75k	0.000080% € 91.1k
Diane Souza	Independent Director	7.9yrs	€217.00k	0.00010% € 113.9k
Thomas Sudhof	Independent Director	7.9yrs	€222.50k	0.00010% € 113.9k
Rachel Duan	Independent Director	4yrs	€145.50k	0.000080% € 91.1k
Christophe Babule	Director	5.2yrs	€134.50k	0.000080% € 91.1k

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: SAN's board of directors are considered experienced (4.8 years average tenure).

Sanofi Management

Management criteria checks 3/4

Key information

Recent management updates

Sanofi Announces CFO Changes, Effective April 1, 2024

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Price target decreased by 8.3% to €106

Third quarter 2023 earnings: EPS misses analyst expectations

Sanofi Reiterates Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 18%

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Is There An Opportunity With Sanofi's (EPA:SAN) 47% Undervaluation?

Second quarter 2023 earnings: EPS misses analyst expectations

Sanofi Provides Earnings Guidance for the Year 2023

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age